37194514|t|[Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
37194514|a|Alzheimer's disease (AD) treatment includes both non-pharmacological and pharmacological approaches. Current pharmacological approaches include symptomatic and disease-modifying therapies (DMTs). In Japan, DMTs have not yet been approved for treating AD; however, four drugs are currently available for symptomatic therapies, including cholinesterase inhibitors (ChEIs) such as donepezil for mild-to-severe dementia, galantamine and rivastigmine for mild-to-moderate dementia, and memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, for moderate-to-severe dementia. In this review, we describe the use of four symptomatic anti-AD drugs in clinical practice for AD.
37194514	6	14	Dementia	Disease	MESH:D003704
37194514	27	46	Alzheimer's Disease	Disease	MESH:D000544
37194514	56	75	Alzheimer's disease	Disease	MESH:D000544
37194514	77	79	AD	Disease	MESH:D000544
37194514	307	309	AD	Disease	MESH:D000544
37194514	434	443	donepezil	Chemical	MESH:D000077265
37194514	463	471	dementia	Disease	MESH:D003704
37194514	473	484	galantamine	Chemical	MESH:D005702
37194514	489	501	rivastigmine	Chemical	MESH:D000068836
37194514	523	531	dementia	Disease	MESH:D003704
37194514	537	546	memantine	Chemical	MESH:D008559
37194514	623	631	dementia	Disease	MESH:D003704
37194514	694	696	AD	Disease	MESH:D000544
37194514	728	730	AD	Disease	MESH:D000544
37194514	Negative_Correlation	MESH:D005702	MESH:D003704
37194514	Negative_Correlation	MESH:D005702	MESH:D000544
37194514	Negative_Correlation	MESH:D008559	MESH:D003704
37194514	Negative_Correlation	MESH:D000077265	MESH:D000544
37194514	Negative_Correlation	MESH:D008559	MESH:D000544
37194514	Negative_Correlation	MESH:D000068836	MESH:D000544
37194514	Negative_Correlation	MESH:D000068836	MESH:D003704
37194514	Negative_Correlation	MESH:D000077265	MESH:D003704

